Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL467003 | 0.95 | — | — | |
| SCHEMBL16466504 | 0.90 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL7661885 | 0.77 | — | — | |
| SCHEMBL467466 | 0.75 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL25393582 | 0.72 | — | — | |
| SCHEMBL17027551 | 0.72 | — | — | |
| SCHEMBL22500020 | 0.69 | PNMT (0.32) | — | |
| SCHEMBL27536090 | 0.65 | — | — | |
| SCHEMBL1929753 | 0.60 | — | — | |
| SCHEMBL23330238 | 0.60 | ALDH1A1 (0.57) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1427 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4337639-A1 | NAMPT INHIBITORS AND USES THEREOF | Remedy Plan, Inc. (US) | 2024-03-20 | — | — | EP | claimed |
| WO-2022241257-A1 | NAMPT INHBITORS AND USES THEREOF | REMEDY PLAN, INC. (US) | 2022-11-17 | — | — | WO | claimed |
| US-12042513-B2 | Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024151519-A2 | PPARG MODULATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| CN-118339152-A | Macrocyclic compounds having farnesyl transferase inhibitory activity | 库拉肿瘤学公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20240228671-A1 | POLYPEPTIDYL LINKERS | Quantum-Si Incorporated (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226302-A1 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-3621958-B1 | PHOTOCHROMIC INDENO FUSED PHENANTHRENOPYRAN COMPOUNDS | TRANSITIONS OPTICAL LTD (IE) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024145281-A1 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-2229376-A1 | INDOLE-SUBSTITUTED 3-CYANOPYRIDINES AS KINASE INHIBITORS | Wyeth LLC (US) | 2010-09-22 | — | — | EP | disclosed |
| WO-2010045442-A1 | ANSAMYCIN HYDROQUINONE COMPOSITIONS | INFINITY DISCOVERY, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009126691-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009076571-A1 | INDOLE-SUBSTITUTED 3-CYANOPYRIDINES AS KINASE INHIBITORS | WYETH (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076602-A1 | 5-ALKYL/ALKENYL-3-CYANOPYRIDINES AS KINASE INHIBITORS | WYETH (US) | 2009-06-18 | — | — | WO | disclosed |
| US-6355640-B1 | TREATMENT OF HYPERTENSION, UROGENITAL DISORDERS AND FORMED BY WITTIG REACTION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-5773530-A | USEFUL AS PSYCHOSTIMULANTS, ANTIHYPERTENSIVE AGENTS AND REMEDIES FOR RENAL FAILURE, DIURETICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-30 | — | — | US | disclosed |
| EP-0737193-A1 | PYRAZOLOPYRIDINE ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-16 | — | — | EP | disclosed |
| WO-1995018128-A1 | PYRAZOLOPYRIDINE ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226302-A1 | BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA | CPT1B, IGF2BP2, IGF2BP3 | ALDH1A1 3101/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | ALDH1A1 638/4885 |
| US-20240228671-A1 | POLYPEPTIDYL LINKERS | VIP, DNPEP, PREP | ALDH1A1 1569/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ALDH1A1 128/4885 |
| US-12042513-B2 | Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof | CRBN, PSMA6, PSMA3 | ALDH1A1 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.